Artisan Partners Limited Partnership Alnylam Pharmaceuticals, Inc. Transaction History

Artisan Partners Limited Partnership

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $14.1 Million - $19.9 Million	-117,345 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$127.18 - $173.91 $15.5 Million - $21.2 Million	-121,791 Reduced 50.93%	117,345 $19.2 Million
Q4 2021 Feb 11, 2022	SELL	$159.56 - $209.29 $582,074 - $763,489	-3,648 Reduced 1.5%	239,136 $40.6 Million
Q3 2021 Nov 12, 2021	BUY	$169.75 - $207.73 $713,289 - $872,881	4,202 Added 1.76%	242,784 $45.8 Million
Q2 2021 Aug 12, 2021	BUY	$128.63 - $176.89 $1.34 Million - $1.84 Million	10,394 Added 4.56%	238,582 $40.4 Million
Q1 2021 May 11, 2021	BUY	$126.83 - $175.69 $3.55 Million - $4.92 Million	28,015 Added 14.0%	228,188 $32.2 Million
Q4 2020 Feb 10, 2021	BUY	$122.97 - $147.0 $4.49 Million - $5.36 Million	36,481 Added 22.29%	200,173 $26 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $4.47 Million - $6.1 Million	36,867 Added 29.07%	163,692 $23.8 Million
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $2.15 Million - $3.22 Million	20,599 Added 19.39%	126,825 $18.8 Million
Q1 2020 May 12, 2020	BUY	$93.12 - $133.99 $9.89 Million - $14.2 Million	106,226 New	106,226 $11.6 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Artisan Partners Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Artisan Partners Limited Partnership with notifications on news.